PT  - JOURNAL ARTICLE
AU  - Bansal, Devendra
AU  - Atia, Hassan
AU  - Badr, Mashael Al
AU  - Nour, Mohamed
AU  - Abdulmajeed, Jazeel
AU  - Hasan, Amal
AU  - Al-Hajri, Noora
AU  - Ahmed, Lina
AU  - Ibrahim, Rumissa
AU  - Zamel, Reham
AU  - Mohamed, Almuthana
AU  - Pattalaparambil, Hamad
AU  - Daraan, Faisal
AU  - Chaudhry, Adil
AU  - Oraby, Sahar
AU  - El-Saleh, Sahar
AU  - El-Shafie, Sittana S
AU  - Al-Farsi, Affra Faiz
AU  - Paul, Jiji
AU  - Ismail, Ahmed
AU  - Al-Romaihi, Hamad E.
AU  - Al-Thani, Mohammed H
AU  - Doi, Suhail A.R.
AU  - Zughaier, Susu M
AU  - Cyprian, Farhan
AU  - Farag, Elmobashar
AU  - Farooqui, Habib Hasan
TI  - Dynamics of anti-S IgG antibodies titers after the second dose of COVID 19 mRNA and non-mRNA vaccines in the manual and craft worker population of Qatar
AID  - 10.1101/2022.08.24.22279159
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.08.24.22279159
4099  - http://medrxiv.org/content/early/2022/08/25/2022.08.24.22279159.short
4100  - http://medrxiv.org/content/early/2022/08/25/2022.08.24.22279159.full
AB  - Background There is limited seroepidemiological evidence on the magnitude and long-term durability of antibody titers of mRNA and non-mRNA vaccines in the Qatari population. This study was conducted to generate evidence on long-term anti-S IgG antibodies titers and their dynamics in individuals who have completed a primary COVID-19 vaccination schedule.Methods A total of 300 participants who received any of the following vaccines BNT162b2/Comirnaty or mRNA-1273 or ChAdOx1-S/Covishield or COVID-19 Vaccine Janssen/Johnson or BBIBP-CorV or Covaxin were enrolled in our study. All sera samples were tested by chemiluminescent microparticle immunoassay (CMIA) for the quantitative determination of IgG antibodies to SARS-CoV-2, receptor-binding domain (RBD) of the S1 subunit of the spike protein of SARS-CoV-2. Antibodies against SARS-CoV-2 nucleocapsid (SARS-CoV-2 N-protein IgG) were also determined. Kaplan–Meier survival curves were used to compare the time from the last dose of the primary vaccination schedule to the time by which anti-S IgG antibodies titers fell into the lowest quartile (range of values collected) for the mRNA and non-mRNA vaccines.Results Participants vaccinated with mRNA vaccines had higher median anti-S IgG antibody titers. Participants vaccinated with the mRNA-1273 vaccine had the highest median anti-S-antibody level of 13720.9 AU/mL (IQR 6426.5 to 30185.6 AU/mL) followed by BNT162b2 (median, 7570.9 AU/ml; IQR, 3757.9 to 16577.4 AU/mL); while the median anti-S antibody titer for non-mRNA vaccinated participants was 3759.7 AU/mL (IQR, 2059.7-5693.5 AU/mL). The median time to reach the lowest quartile was 3.53 months (IQR, 2.2-4.5 months) and 7.63 months (IQR, 6.3-8.4 months) for the non-mRNA vaccine recipients and Pfizer vaccine recipients, respectively. However, more than 50% of the Moderna vaccine recipients did not reach the lowest quartile by the end of the follow-up period.Conclusions This evidence on anti-S IgG antibody titers, their durability and decay over time should be considered for the utility of these assays in transmission dynamics after the full course of primary vaccination.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for this research was obtained from Research Committee at MOPH (ERC-826-3-2020) and the Human Ethics Institutional Review Board at Primary Health Care Corporations (PHCC/DCR/2020/09/103), Qatar.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript